home / stock / ruby / ruby news

RUBY News and Press, Rubius Therapeutics Inc. From 03/28/19

Stock Information
Company Name: Rubius Therapeutics Inc.
Stock Symbol: RUBY
Market: OTC
Website: rubiustx.com
Menu
RUBY RUBY Quote RUBY Short RUBY News RUBY Articles RUBY Message Board
Get RUBY Alerts

News, Short Squeeze, Breakout and More Instantly...
RUBY - Rubius Therapeutics beats by $0.07

Rubius Therapeutics (NASDAQ: RUBY ): Q4 GAAP EPS of -$0.35  beats by $0.07 . More news on: Rubius Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

RUBY - Rubius Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results with Business Updates

Investigational New Drug Application Cleared for First-Ever Red Cell Therapeutic™, RTX-134, for Treatment of Phenylketonuria Data from Company’s Oncology Pipeline to be Presented at AACR 2019 Annual Meeting CAMBRIDGE, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Rubius T...

RUBY - Rubius Therapeutics Appoints Natalie Holles to its Board of Directors and Greg Whitehead as Senior Vice President and Chief Quality Officer

CAMBRIDGE, Mass., March 25, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, today announced the appointment of Natalie Ho...

RUBY - Rubius Therapeutics to Announce Fourth Quarter and Full-Year 2018 Financial Results

CAMBRIDGE, Mass., March 19, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, today announced plans to report fourth quart...
RUBY - Rubius Therapeutics (RUBY) Presents At Cowen and Company 39th Annual Health Care Conference - Slideshow

The following slide deck was published by Rubius Therapeutics, Inc. in conjunction with this Read more ...

RUBY - Rubius Therapeutics Announces FDA Clearance of Investigational New Drug Application for First-Ever Red Cell Therapeutic, RTX-134, for Treatment of Phenylketonuria

CAMBRIDGE, Mass., March 11, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, today announced that the U.S. Food and Drug Administration (...

RUBY - Rubius Therapeutics (RUBY) Presents At SVB Leerink 8th Global Healthcare Conference - Slideshow

The following slide deck was published by Rubius Therapeutics in conjunction with this Read more ...

RUBY - Rubius Therapeutics Announces Poster Presentations at the 2019 American Association for Cancer Research Annual Meeting

CAMBRIDGE, Mass., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, today announced that the company will present preclinical dat...

RUBY - Rubius Therapeutics to Participate at Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, today announced that Pablo J. Cagnoni, M.D., chief executive ...

Previous 10 Next 10